PharmAla Biotech Logo 800 x 422.png
PharmAla Closes Private Placement and Concurrent Debt Settlement
19. April 2024 08:35 ET | PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
PharmAla Biotech Logo 800 x 422.png
PharmAla Announces Private Placement and Concurrent Debt Settlement
10. April 2024 16:30 ET | PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
PharmAla Biotech Logo 800 x 422.png
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
05. April 2024 08:58 ET | PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
PharmAla Biotech Logo 800 x 422.png
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
27. März 2024 08:00 ET | PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Signs Sale Agreement with Numinus
26. März 2024 08:55 ET | PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
P-1 molecular structure
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
20. März 2024 10:20 ET | PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
PharmAla Biotech Logo 800 x 422.png
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18. März 2024 08:55 ET | PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Biotech Logo 800 x 422.png
PharmAla named an Intellectual Property Ontario Client
22. Februar 2024 08:55 ET | PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Biotech Logo 800 x 422.png
PharmAla Data to be Published in ACS Chemical Neuroscience
20. Februar 2024 08:55 ET | PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans